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Abstract
Background: The tripeptide feG (D-Phe-D-Glu-Gly) is a potent anti-inflammatory peptide that
reduces the severity of type I immediate hypersensitivity reactions, and inhibits neutrophil
chemotaxis and adhesion to tissues. feG also reduces the expression of β1-integrin on circulating
neutrophils, but the counter ligands involved in the anti-adhesive actions of the peptide are not
known. In this study the effects of feG on the adhesion of rat peritoneal leukocytes and
extravasated neutrophils to several different integrin selective substrates were evaluated.
Results: The adhesion of peritoneal leukocytes and extravasated neutrophils from rats to adhesive
proteins coated to 96-well plates was dependent upon magnesium (Mg2+) ion, suggestive of
integrin-mediated adhesion. feG inhibited leukocyte adhesion, but only if the cells were stimulated
with PAF (10-9M), indicating that feG's actions in vitro require cell activation. In the dose range of
10-10M to 10-12M feG inhibited the adhesion of peritoneal leukocytes to fibrinogen and fibronectin,
but not IgG, vitronectin or ICAM-1. feG inhibited the binding of extravasated neutrophils to
heparin, IgG, fibronectin and CD16 antibody. Antigen-challenge of sensitized rats reduced the
adhesion of peritoneal leukocytes to most substrates and abolished the inhibitory effects of feG.
However, pretreating the animals with intraperitoneal feG (100 μg/kg) 18 h before collecting the
cells from the antigen-challenged animal restored the inhibition of adhesion by in vitro feG of
peritoneal leukocytes and extravasated neutrophils to fibronectin.
Conclusion: The modulation of leukocyte adhesion by feG appears to involve actions on αMβ2
integrin, with a possible interaction with the low affinity FcγRIII receptor (CD16). The modulation
of cell adhesion by feG is dual in nature. When administered in vivo, feG prevents inflammation-
induced reductions in cell adhesion, as well as restoring its inhibitory effect in vitro. The mechanism
by which in vivo treatment with feG exerts these effects remains to be elucidated.
Background
The tripeptide FEG (Phe-Glu-Gly) was isolated from rat
submandibular glands as a component of a heptapeptide
(SGPT) located at the C-terminal end transcript of the var-
iable coding sequence a1 gene (Vcsa1; also known as a
submandibular rat 1 gene; (SMR1)) [1,2]. The D-isomer
of FEG (feG), is active in all species tested to date includ-
ing mice [3], sheep [4], cats [5], dogs and isolated human
neutrophils [6]. The peptide has potent anti-inflamma-
tory action that effectively reduces allergic or type I imme-
diate hypersensitivity reactions, as revealed by attenuated
vascular leakage, intestinal motility disturbances, systemic
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hypotension, bronchoconstriction and hyper-reactivity,
and pulmonary inflammation [4,7-10]. Additionally,
these peptides modulate neutrophil function by inhibit-
ing their adhesion, chemotaxis, and production of intrac-
ellular superoxide [6,11-13].
By interfering with leukocyte adhesion and chemotaxis,
feG arrests the movement of cells into the extravascular
space and prevents their migration to the site of inflam-
mation [7,14], thereby reducing the severity of the inflam-
mation. Some of the anti-adhesive actions of feG stem
from the peptide modifying the expression of integrins
and the binding properties of the integrin-associated IgG
receptor – CD16 (FcγRIII) [6,10,12]. The integrins, het-
erodimeric cell surface receptors involved in diverse bio-
logical responses from embryonic development,
thrombosis, and immune and inflammatory responses,
are essential players in the adhesion, extravasation and
migration of leukocytes [15,16].
The objective of this study was to further characterize the
specificity of feG's inhibitory action on leukocyte adhe-
sion by examining adhesion to substrates that show selec-
tivity for the integrins expressed on neutrophils. These
include: highly expressed β2-integrins,  αLβ2 (CD11a/
CD18) and αMβ2 (CD11b/CD18), and others that are
poorly expressed, such as αXβ2 (CD11c/CD18), α2β1
(CD49b/CD29),  α4β1 (CD49d/CD29), α5β1(CD49e/
CD29), and αVβ3 (CD51/CD61) [17-19]. α4β1 is of
interest because its expression is up-regulated on activated
neutrophils [12,17-19].
Methods
Animal groups and sensitization
The protocols for all animal experiments were approved
by the University of Calgary Health Sciences Animal Care
Committee, which conforms to the guidelines of the
Canadian Council on Animal Care. Male Sprague-Dawley
rats (Charles River Canada, Saint-Constant, QC), of an
initial weight or 160–175 g, were housed under control-
led lighting conditions (lights on from 7:00 H to 19:00
H), and provided with food and water ad libitum. Previous
studies have established that feG does not affect leukocyte
function in normal animals or cells, but its effects are
revealed upon imposition of an inflammatory stimulus
[6,7,10,20]. Thus, several groups of animals were used
that included: 1) normal, unsensitized rats; 2) unsensi-
tized rats treated with 100 μg/kg feG 18 h before harvest-
ing the cells; 3) ovalbumin (OA)-sensitized rats
challenged with antigen 18 h before harvesting cells; and
4) ovalbumin-sensitized rats challenged with antigen and
treated with 100 μg/kg feG 18 h before harvesting cells.
feG has a half-life of approximately 12 h [21], and in sev-
eral studies pre-treatment with feG 18 h before leukocyte
isolation has demonstrated attenuated inflammatory
responses to endotoxin and allergen [12,14].
Rats were sensitized with an intraperitoneal injection of 1
mg OA and 50 ng pertussis toxin (Sigma Chemical, St.
Louis, Mo.) as adjuvant: a sensitization method generat-
ing elevated IgE titres [22,23]. The animals were used 28
to 35 days post-sensitization. Rats received oral antigen by
gastric lavage with 100 mg/kg of OA in 0.9% saline,
whereas unchallenged sensitized animals received a neu-
tral antigen, bovine serum albumin (BSA).
Leukocyte preparation
Leukocytes were obtained from three sources: blood, the
peritoneal cavity or a carrageenan-soaked, implanted
sponge. Underhalothane anaesthesia 9–10 mL of blood
was collected by cardiac puncture into a 12 mL syringe,
containing 1 ml of 3.8% Na citrate, an anticoagulant. The
blood (10–12 mL) was diluted with polymorphonuclear
leukocyte (PMN) buffer without calcium to 50 mL in a
polypropylene centrifuge tube, and centrifuged at 400 g
for 15 min at 4°C. The PMN buffer was of the following
composition: 138 mM NaCl, 2.7 mM KCl, 3.2 mM
Na2HPO4.12H2O, 5.5 mM glucose. The white blood cells
were removed from the surface of the pellet with a plastic
Pasteur pipette, and contaminating red blood cells were
lysed with 4 volumes of 0.15 M NH4Cl for 10 min at room
temperature. The volume of the polypropylene centrifuge
tube was completed to 50 mL with PMN buffer without
calcium, and after a second spin at 400 g for 10 min at
4°C, the supernatant was discarded. The pellet was
washed with calcium free PMN buffer and centrifuged
again at 400 g for 10 min at 20°C. The supernatant was
discarded and the cells resuspended in 1 mL of PMN
buffer containing calcium (1.2 mM CaCl2), magnesium
(1.5 mM MgCl2).
Peritoneal cells were obtained by injecting 10 ml of 0.9%
saline into the peritoneum, and after massaging, a
laparotomy was performed and the saline aspirated with
a plastic Pasteur pipette. The cells were washed twice in
calcium free PMN buffer as described for the blood cells
before resuspending them in Ca2+-PMN buffer.
Extravasated neutrophils were collected by placing, under
halothane anaesthesia, a small sponge soaked in 0.5%
carrageenan subcutaneously into the intrascapular region
[24]. To implant the sponge a 2–3 cm incision was made
dorsally, between the shoulder blades, and connective tis-
sue was cleared from the exposed area. The skin was then
closed with sutures of 3-0 Dexon thread. Eighteen hours
later the sponge was removed and the fluid was squeezed
from it into 5 mLs of PMN buffer. Following centrifuga-
tion at 400 g for 10 min, the exudate was decanted and the
remaining cells were suspended in Ca2+-PMN buffer. TotalJournal of Inflammation 2008, 5:6 http://www.journal-inflammation.com/content/5/1/6
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leukocyte counts were determined with a Hylite hemocy-
tometer (Hauser Scientific, Boulder, CO) using Trypan
Blue exclusion as a marker of cell viability.
Adhesion assay
Leukocyte adhesion was performed using modifications
of a crystal violet assay [25-27]. The wells of 96-cell poly-
styrene Nunclon plates (Nalge Nunc International,
Naperville, IL) were coated with various substrate mole-
cules, using literature cited amounts – fibrinogen (500 ng/
ml; [28]), fibronectin (2.5 μg/ml; [29]), rat serum IgG (10
μg/ml; [30]), or vitronectin (350 ng/ml; [31]). The plates
were allowed to dry at room temperature overnight, then
washed twice with 0.9% saline, dried again and then
stored at 4°C until use within 2–3 weeks. Leukocytes(2.5
× 10 5 in 200 μl of PMN buffer) were distributed into the
protein-coated wells and different final concentrations
(10-10M to 10-12M) of the peptide feG were added (10 μL)
to separate wells. The cells were allowed to adhere for 45
min at 37°C. The wells were then washed 3 times in 200
μl of PMN buffer, fixed with 10% formalin for 10 min,
before adding crystal-violet (crystal-violet 7·5 g/l, NaCl
2·5 g/l, formaldehyde 1·57%, methanol 50%) for an
additional 5 min. The cells were washed 3 times with dis-
tilled water, solubilized with 10% sodium dodecyl sul-
phate (SDS), and the plates were read at 540 nm
(Multiskan Ascent, Thermo Scientific, Waltham, MA).
After subtraction of non-specific colorimetric readings to
obtain absolute binding, the percent inhibition of leuko-
cyte adhesion by feG was calculated relative to the wells
containing only PAF (10-9M).
The adhesion of neutrophils to various antibodies to var-
ious cell adhesion molecules was evaluated using anti-rat
CD11b (clone OX-42; isotype – IgG2a; BD-Pharmingen,
San Diego, CA); mouse anti-rat CD18 (clone WT.3; iso-
type – IgG1; AbD Serotec, Cedarlane Laboratories Ltd;
Hornby ON); mouse anti-Rat CD32 (Clone: D34-485;
isotype – IgG1; RDI Research Diagnostics Inc., Concord
MA); hamster anti-rat CD62L (Clone: HRL1; isotype –
IgG2a; BD-Pharmingen) and anti-human CD16 (clone
LNK16; isotype – IgG1; Advanced ImmunoChemical Inc,
Long Beach, CA). 0.1 μg of antibody was added to each
well of a 96-well plate [32], and the adhesion study per-
formed as described above.
Peptides and Chemicals
feG was synthesized by American Peptide Co., Sunnyvale,
CA. Platelet activating factor PAF(C16) (1-Hexadecyl-2-
acetyl-sn-glycero-3-phosphocholine), obtained from
Sigma-Aldrich, St. Louis was dissolved in 100% ethanol at
a concentration of 10-2M and stored at -20°C in 5 μl aliq-
uots, and diluted 107 fold for use at a final concentration
of 10-9M. Rat tail collagen, IgG from rat sera, vitronectin
from human plasma were purchased from Sigma-Aldrich.
Fibrinogen (plasminogen-depleted from human plasma)
was obtained from Calbiochem, San Diego, CA. Fibronec-
tin (human) BD Biosciences, San Jose, CA Recombinant
human soluble ICAM-1 from Bender MedSystems Inc.
Burlingame, CA. Heparin was from Organon Canada Ltd.
Toronto, ON.
Statistical analysis
The results are presented as the mean ± SEM. The statisti-
cal functions used are associated with Excel (Microsoft
Office XP, Redmond, WA). Comparisons between treat-
ment groups were made with one-way analysis of variance
(ANOVA), and if warranted differences between two
groups were evaluated using the unpaired Student's t-test.
Statistical values reaching probabilities of p < 0.05 were
considered significant.
Results
General characteristics of leukocyte adhesion
Adhesion of circulating and peritoneal leukocytes, as well
as extravasated neutrophils, to fibrinogen and fibronectin
increased significantly when magnesium ion (Mg2+) was
present in the buffer. The adhesion of blood leukocytes,
predominately monocytes/lymphocytes, was at least 50%
less than that of peritoneal cells (macrophages and neu-
trophils) and extravasated neutrophils. Due to this low
adhesion of blood leukocytes the effects of feG on adhe-
sion were evaluated using peritoneal leukocytes and
extravasated neutrophils.
In a previous study stimulation with PAF (10-9M) was
required to observe an inhibitory effect of feG both on rat
leukocyte adhesion to atrial tissue [20], and inhibition of
CD16 antibody binding to human neutrophils [6]. This
requirement for PAF also was observed for feG (10-11M)
inhibition of adhesion of peritoneal leukocytes from
unsensitized animals to fibrinogen and fibronectin (Fig-
ure 1A). Similar results were seen with extravasated neu-
trophils adhesion to fibronectin (Figure 1B), although feG
did not inhibit the adhesion of these cells to fibrinogen
(Figure 1B) or IgG (not shown). Extravasated neutrophils
did not bind to collagen. For all subsequent experiments
PAF was included in the adhesion assay.
Effects of sensitization and an allergic reaction
The presence of an allergic response in the sensitized rats
was established by monitoring differential cell counts in
blood [12]. Antigen challenge of sensitized animals
caused a circulating neutrophilia (48.7 ± 4.4% of circulat-
ing white blood cells) that was ~2.5 times greater than
that of unsensitized animals (19.2 ± 2.9%). Treatment
with feG did not alter white blood cell counts in unsensi-
tized animals, but effectively prevented the neutrophilia
occurring in sensitized animals (28.9 ± 3.4%).Journal of Inflammation 2008, 5:6 http://www.journal-inflammation.com/content/5/1/6
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Changes, reported below, in cell adhesion with sensitized
animals were not due to differential cell numbers in the
peritoneal lavage fluid or in the carrageenan-soaked
sponge, since peritoneal lavage fluid contained 11 to 12%
neutrophils and 35 to 43% macrophages and was the
same in the 4 animal groups studied. The carrageenan-
soaked sponge cells were >99% neutrophils in all animal
groups.
When cells were collected from sensitized animals that
were not challenged with antigen, the adhesion of perito-
neal leukocytes to any of the substrates was not signifi-
cantly different from that seen with unsensitized animals
(not shown). However, when peritoneal leukocytes were
collected from antigen-challenged animals, lower adhe-
sion to heparin, fibrinogen, fibronectin and vitronectin
(Figures 2A, C, D and 2E) but not to IgG (Figure 2B) was
observed. Treatment with feG (100 μg/kg) at the time of
antigen challenge reversed this antigen-induced reduction
in adhesion to these substrates except for heparin. The
adhesion of extravasated neutrophils to IgG and fibrino-
gen was not affected by antigen challenge (Figures 3B and
2C), although adhesion to heparin of the extravasated
cells was reduced (Figure 3A) and adhesion to fibronectin
was increased. With unsensitized animals the extravasated
neutrophils did not adhere to vitronectin (Figure 3E),
although antigen challenge of the sensitized animals
resulted in significant adhesion to vitronectin.
Effects of ex vivo feG on leukocyte adhesion
Figure 4 shows dose response relationships (10-10M to 10-
12M; [6,12]) for the inhibitory effect of feG on PAF-stimu-
lated peritoneal leukocytes from unsensitized rats that
were not pretreated with feG (Figure 4A), and those that
received intraperitoneal feG (100 μg/kg) 18 hr before iso-
lating the cells (Figure 4B). With cells from animals that
were not pretreated with feG (Figure 4A), the ex vivo addi-
tion of feG to the assay wells at 10-10M and 10-11M inhib-
ited leukocyte adhesion to fibrinogen by 24.2 ± 3.7% and
14.3 ± 4.4%, respectively, and to fibronectin by 17.3 ±
8.4% and 16.0 ± 5.3%, respectively. Peritoneal leukocytes
from unsensitized animals avidly bound to ICAM-1 (OD
of 2.36 ± 0.08/106 cells), although feG did not affect the
adhesion to this substrate (not shown).
In contrast, with feG pretreatment (Figure 4B), the inhibi-
tion of adhesion of peritoneal leukocytes to fibronectin
and fibrinogen increased significantly to an average of
32.0 ± 7.5% and 31.7 ± 6.1%, respectively, for the three
concentrations of feG. A sensitization of the leukocytes to
the inhibitory effect of ex vivo feG occurred as the signifi-
cant inhibition of adhesion seen with 10-12M peptide was
absent if the animals were not pretreated with feG.
The inhibitory effects of ex vivo feG on peritoneal leuko-
cyte adhesion to fibrinogen and fibronectin were abol-
ished when sensitized animals were challenged with
antigen (Figure 2). However, the in vivo pretreatment with
feG re-established the inhibitory effect of feG on adhesion
to fibronectin, but not fibrinogen (Figure 2C and 2D).
With extravasated neutrophils from unsensitized animals
ex vivo feG only inhibited adhesion to heparin (Figure
3A), and with antigen-challenged animals inhibition of
adhesion of these cells to IgG occurred (Figure 3B). Pre-
treatment with feG enabled an inhibitory effect of ex vivo
feG on extravasated neutrophil adhesion to IgG in unsen
PAF is required for inhibition of adhesion by feG Figure 1
PAF is required for inhibition of adhesion by feG. The 
inclusion of PAF (10-9M) was required to observe an inhibi-
tory effect of feG (10-11M) on the adhesion of peritoneal leu-
kocytes from unsensitized animals to fibrinogen and 
fibronectin. With extravasated neutrophils feG inhibition of 
adhesion only occurred in the presence of PAF for fibronec-
tin. Control (black column), feG (open column; 10-11M), PAF 
(crossed column), and PAF + feG (lined column). Mean ± 
SEM; p < 0.05; * = less than corresponding controls; n ≥ 4 for 
each group of cells and substrate.
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Effects of feG on the adhesion of peritoneal leukocytes to heparin, IgG, fibrinogen, fibronectin and vitronectin Figure 2
Effects of feG on the adhesion of peritoneal leukocytes to heparin, IgG, fibrinogen, fibronectin and vitronectin. Three different types of 
results are summarized: 1) the effects of antigen challenge (Ag); 2) the effects of in vivo treatment with feG (i.p. feG); and 3) the effects of ex vivo feG (open 
column). The adhesion, expressed as optical density (O.D.) for 1 million cells, is shown in the presence of PAF (10-9M) alone (black column), and in the 
presence of PAF and ex vivo feG (open column). The adhesion in the presence of ex vivo feG is the average adhesion for 10-10M to 10-12M feG added to the 
cells in the 96-well plate bars. Results are shown for four groups of animals: unsensitized (Unsens); unsensitized treated intraperitoneally with feG 18 h 
before harvesting the cells (Unsens + i.p. feG); antigen-challenged sensitized (Ag); and antigen-challenged sensitized treated intraperitoneally with feG 18 h 
before harvesting the cells (Ag + i.p. feG). Mean ± SEM; p < 0.05. # less than corresponding unsensitized group; χ greater than unsensitized group; * less 
than corresponding control (PAF alone); δ greater than no i.p. feG; X greater than corresponding unsensitized group. n ≥ 4 for each group of cells.
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Effects of feG on the adhesion of carrageenan neutrophils to heparin, IgG, fibrinogen, fibronectin and vitronectin Figure 3
Effects of feG on the adhesion of carrageenan neutrophils to heparin, IgG, fibrinogen, fibronectin and vitronectin. Three different types of 
results are summarized: 1) the effects of antigen challenge (Ag); 2) the effects of in vivo treatment with feG (i.p. feG); and 3) the effects of ex vivo feG (open 
column). The adhesion, expressed as optical density (O.D.) for 1 million cells, is shown in the presence of PAF (10-9M) alone (black column), and in the 
presence of PAF and ex vivo feG (open column). The adhesion in the presence of ex vivo feG is the average adhesion for 10-10M to 10-12M feG added to the 
cells in the 96-well plate bars. Results are shown for four groups of animals: unsensitized (Unsens); unsensitized treated intraperitoneally with feG 18 h 
before harvesting the cells (Unsens + i.p. feG); antigen-challenged sensitized (Ag); and antigen-challenged sensitized treated intraperitoneally with feG 18 h 
before harvesting the cells (Ag + i.p. feG). Mean ± SEM; p < 0.05. # less than corresponding unsensitized group; χ greater than unsensitized group; * less 
than corresponding control (PAF alone); δ greater than no i.p. feG; X greater than corresponding unsensitized group. n ≥ 4 for each group of cells.
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sitized rats (Figure 3B) and fibronectin with sensitized rats
(Figure 3D).
Effects of feG on leukocyte adhesion to antibodies
Since feG inhibits the binding of CD11b and CD16b anti-
body to human neutrophils [6], the effects of feG on the
adhesion of extravasated neutrophils to integrin antibod-
ies and CD16b were evaluated. feG did not modify neu-
trophil adhesion to CD18b (β2 integrin), CD62L (L-
selectin) or CD32 (FcγRII; intermediate affinity IgG recep-
tor) (not shown). feG modestly, but dose-dependently,
inhibited the adhesion of neutrophils to human CD16
(FcγRIII; intermediate affinity IgG receptor) antibody, and
at the highest dose tested (10-9M) inhibited neutrophil
adhesion to CD11b antibody by 24 % (Figure 5). The
inhibition of adherence to CD11b and CD16 antibodies
by feG is not due to non-specific binding effects as anti-
CD62L was the same isotype as anti-CD11b (IgG2a), and
anti-CD18 and anti-CD32 were the same isotype (IgG1)
as CD16.
Discussion
In keeping with other studies using human neutrophils
[33,34], we found that the adhesion of rat leukocytes
required the presence of Mg2+ ion in the incubating buffer,
indicating that leukocyte adhesion is mediated by an
integrin possessing a metal ion-dependent adhesion site
(MIDAS). This Mg2+/Mn2+ binding site is located in the I
domain of seven integrin α-subunits (α1, α2, αL, αM, αX,
αD, αV and αE) [35]. The requirement of cell stimulation
with PAF (Figure 1) for feG to inhibit adhesion reflects
previous results showing that leukocytes activation was
essential for feG to inhibit cell adhesion to atrial tissue
[20], binding of CD16 antibody to neutrophils [6] and
superoxide production [12]. Although the molecular basis
for this activation requirement for an effect of feG is not
known functional activation by pro-inflammatory media-
tors with resulting changes in integrin affinity is a com-
mon feature of integrin-mediated actions [36,37].
The tripeptide feG was found to inhibit leukocyte adhe-
sion to several integrin-selective substrates, although the
identity of the specific integrin was not conclusively iden-
Dose-dependent inhibition of neutrophil adhesion to anti- bodies Figure 5
Dose-dependent inhibition of neutrophil adhesion to 
antibodies. Inhibition by feG of the adhesion of extrava-
sated neutrophils to CD11b (black circle) and CD16b (black 
square). Mean ± SEM; p < 0.05; * = significant inhibition. n ≥ 7 
for each antibody and the different doses of feG.
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Dose-dependent inhibition of peritoneal leukocyte adhesion  to fibrinogen and fibronectin Figure 4
Dose-dependent inhibition of peritoneal leukocyte 
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tified. The inhibition of adhesion of peritoneal leukocytes
to fibrinogen is indicative of modification of αMβ2
integrin-mediated adhesion. Leukocytes can adhere to
fibrinogen by using αMβ2,  αXβ2 and αVβ3 integrins
[15,38]. However, since feG did not modify adhesion to
vitronectin, an αVβ3 integrin selective substrate [39], nor
adhesion to collagen, which interacts preferentially with
αXβ2 (CD11c), α1β1, α2β1, α10β1 and α11β1[40,41]
and  αXβ2 is generally, with some exceptions [42,43],
poorly expressed on neutrophils, feG's probably alters
αM-mediated adhesion. An apparent anomalous observa-
tion is that feG did not modify adhesion to ICAM-1 which
also interacts with αMβ2 [15]. However, the binding sites
on αMβ2 for ICAM-1 and fibrinogen are distinct [44,45],
and other αMβ2 integrin inhibitors block adhesion to
fibrinogen but not to ICAM-1 [46].
An apparent exception to the selectivity of feG interfering
with αMβ2-mediated adhesion is the inhibition by this
peptide of leukocyte and neutrophil adhesion to fibronec-
tin, which is generally considered to adhere to four
integrins (α3β1,  α4β1,  α5β1,  αVβ3) using the RGD
(arginine-glycine-aspartic acid) motif [38]. However, sev-
eral studies have shown that αMβ2 integrin binds to
fibronectin via coordinate interactions with β1 integrins
[47,48]. This interaction may involve initial engagement
of β1 integrins on neutrophils with a resulting cross-talk
signal leading to activation of αMβ2-mediated adhesion
[48]. Thus, feG probably interacts or modifies a restricted
subset of binding sites on the versatile and promiscuous
αMβ2 integrin [38]. Cross-talk between α4β1 and αVβ3
also occurs [49], and may account for the trend towards
inhibitory actions of ex vivo feG on extravasated neu-
trophils binding to vitronectin (Figure 4E).
A previously proposed role for FcγRIII in the actions of feG
[6,50] is supported by the observation that the peptide
inhibited the adhesion of extravasated neutrophils to a
CD16 antibody (Figure 5), and IgG (Figure 3B). αMβ2 is
known to cooperate with FcγRIII for the internalization of
IgG-coated particles [51] and the generation of a respira-
tory burst [52]. In these cells, a physical proximity and
association exists between CD16 and αMβ2 integrin
[53,54]. The absence of an effect of feG on peritoneal leu-
kocyte adhesion to IgG may reflect transient binding
observed for human circulating neutrophils [30].
It is not known whether feG, which has its origins in the
salivary glands of rats [2,55], acts as hormonal regulator of
integrin-mediated adhesive interactions, or reflects a
binding motif on an integrin or an integrin ligand. Most
adhesive interactions between ligands and their substrates
involve "a substrate recognition sequences" [38]. A FEG-
like motif does not exist in IgG, fibrinogen or fibronectin,
thus feG is probably not acting as "substrate recognition
motif" to prevent integrin-substrate interactions. A FEG-
like motif (FEA at F302-A304) is found on the α7 tail of
αM integrin, and this sequence deserves attention as con-
tributing to αM integrin-mediated adhesion. Exogenous
FEG may be acting as a mimic of this α7 tail motif.
Although a FEG sequence is found on laminins, tenascin
C and versican, it is not known if this motif in these pro-
teins serves as a recognition site for adhesive events, which
are generally considered to be mediated by the RGD motif
for laminin interactions with several integrin heterodim-
ers (α1β1, α2β1, α3β1, α6β1, α7β1 and α6β4) [56], as is
the case for tenascin interactions with α5β1[57]. Moreo-
ver, αMβ2 integrins do not play a major role in the adhe-
sion of leukocytes to these extracellular matrix molecules
[31].
The low adhesion of mixed blood leukocytes from rats to
the fibrinogen and fibronectin precluded their study, and
probably reflects the high proportion of lymphocytes/
monocytes in rat blood, which only exhibit significant
adhesion when stimulated with cytokines [58], or to more
complex substrates such as heart tissue or cultured epithe-
lial and endothelial cells [20,58,59]. The reduced adhe-
sion of peritoneal leukocytes from antigen-challenged rats
relative to unsensitized rats (Figure 2) may reflect a state
of unresponsiveness or phenotypic modification of the
cells resulting from the activation of the immediate hyper-
sensitivity reaction. A similar loss of response by neu-
trophils is seen in other pathologies, such as portal
hypertension, sepsis and severe injury [60-62]. Pretreat-
ment with feG (18 h before cell collection) prevents the
development of reduced adhesion in antigen-challenged
animals, as is also seen with the increased production of
intracellular superoxide by circulating neutrophils of anti-
gen-challenged sensitized rats [12]. The reduced adhesion
of peritoneal leukocytes was not due to lower expression
of CD11b, since the surface expression of this integrin was
increased by antigen challenge, and feG pre-treatment
prevented this increase (unpublished observations). In
what appears to be a paradox, antigen challenge had the
opposite effect on extravasated neutrophils, enhancing
their adhesion to fibronectin and vitronectin (Figure 3),
indicating that feG may have differential actions depend-
ing upon the source of the cells, and possibly cross-talk
interactions between integrins discussed above. The basis
of these differences and interactions should become clear
once the mechanism of action of feG is elucidated.
Conclusion
The tripeptide feG, an anti-inflammatory peptide, may
inhibit leukocyte adhesion by interfering with αMβ2
integrin-mediated adhesion. Several facets to feG's actions
exist: an acute ex vivo inhibitory effect; and when the pep-
tide is administered in vivo, a prevention of loss of perito-Journal of Inflammation 2008, 5:6 http://www.journal-inflammation.com/content/5/1/6
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neal leukocyte binding in antigen-challenged animals
with restoration of ex vivo inhibition.
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